<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04291781</url>
  </required_header>
  <id_info>
    <org_study_id>18C014</org_study_id>
    <nct_id>NCT04291781</nct_id>
  </id_info>
  <brief_title>A Study of RC18 Administered Subcutaneously to Subjects With IgA(Immunoglobulin A) Nephropathy</brief_title>
  <official_title>Phase II Clinical Trial of RC18(Recombinant Human B Lymphocyte Stimulator Receptor - Antibody Fusion Protein for Injection) in the Treatment of IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of Tai Ai (Recombinant Human B Lymphocyte Stimulator&#xD;
      Receptor-Antibody Fusion Protein for Injection) in the treatment of IgA nephropathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 13, 2020</start_date>
  <completion_date type="Actual">May 20, 2021</completion_date>
  <primary_completion_date type="Actual">May 20, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 24-hour urine protein excretion level at Week 24;</measure>
    <time_frame>week 24</time_frame>
    <description>24-hour urine protein measures the amount of protein released in urine over a 24-hour period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in eGFR</measure>
    <time_frame>week 0、4、8、12、16、20、24</time_frame>
    <description>eGFR=Estimated Glomerular Filtration Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urine protein/creatine ratio(UPCR) and/or urine albumin/ creatine ratio(UACR)</measure>
    <time_frame>week 0、4、8、12、16、20、24</time_frame>
    <description>Each center tested for UPCR and / or UACR needs to be as consistent as possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the count of urine red blood cells</measure>
    <time_frame>week 0、4、8、12、16、20、24</time_frame>
    <description>The method of measuring the urine red blood cells in each center needs to be as consistent as possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the values of Immunoglobulin G(IgG);</measure>
    <time_frame>week 0、4、8、12、16、20、24</time_frame>
    <description>The content of IgG was detected by immunological index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the values of Immunoglobulin M(IgM);</measure>
    <time_frame>week 0、4、8、12、16、20、24</time_frame>
    <description>The content of IgM was detected by immunological index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the values of Immunoglobulin A(IgA);</measure>
    <time_frame>week 0、4、8、12、16、20、24</time_frame>
    <description>The content of IgG was detected by immunological index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1. Change from baseline in the values of B-lymphocyte (CD19+)</measure>
    <time_frame>week 0、4、8、12、16、20、24</time_frame>
    <description>The content of B-lymphocyte was detected by immunological index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1. Change from baseline in the values of complement 3（C3）</measure>
    <time_frame>week 0、4、8、12、16、20、24</time_frame>
    <description>The content of complement 3 was detected by immunological index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1. Change from baseline in the values of complement 4 (C4)</measure>
    <time_frame>week 0、4、8、12、16、20、24</time_frame>
    <description>The content of complement 4 was detected by immunological index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence rate and severity of adverse events.</measure>
    <time_frame>week 0、4、8、12、16、20、24</time_frame>
    <description>To evaluate the safety of multiple intravitreal injection of each group.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>RC18 160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RC18 160mg SC once weekly ,and total of 24 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC18 240mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RC18 240mg SC once weekly ,and total of 24 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo SC once weekly ,and total of 24 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RC18 160mg</intervention_name>
    <description>subcutaneous injection RC18 160mg on the upper arm, abdomen, or upper thigh outside;</description>
    <arm_group_label>RC18 160mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RC18 240mg</intervention_name>
    <description>subcutaneous injection RC18 240mg on the upper arm, abdomen, or upper thigh outside;</description>
    <arm_group_label>RC18 240mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>subcutaneous injection placebo on the upper arm, abdomen, or upper thigh outside;</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signing the informed consent;&#xD;
&#xD;
          2. Biopsy confirmed diagnosis of IgA nephropathy;&#xD;
&#xD;
          3. Male or female, between 18 and 70 years age;&#xD;
&#xD;
          4. Before randomization, 24-hour urine protein excretion of ≥1g/24h in every screening&#xD;
             visit;&#xD;
&#xD;
          5. Estimated glomerular filtration rate (eGFR) (CKD-EPI formula) of &gt;45 ml/min per&#xD;
             1.73m2;&#xD;
&#xD;
          6. Have received the ACEI(Angiotension converting enzyme inhibitors)/ARB(Angiotensin&#xD;
             receptor blocker) standard treatment for 24 weeks prior to randomization, and have&#xD;
             stabled the dosage (within the maximum tolerated dosage) for 4 weeks prior to&#xD;
             randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant abnormalities in clinical laboratory values (including, but not limited&#xD;
             to, the following indicators)：&#xD;
&#xD;
             Items Abnormal value WBC(white blood cell count) &lt;3*10^9/L PMN(Neutrophil count)&#xD;
             &lt;1.5*10^9/L HGB(hemoglobin) &lt;85g/L PLT(blood platelet count) &lt;80*10^9/L TBil(total&#xD;
             bilirubin) &gt;1.5*ULN ALT(Alanine aminotransferase) &gt;3*ULN AST( Aspartate transaminase)&#xD;
             &gt;3*ULN ALP(alkaline phosphatase) &gt;2*ULN CK(creatine kinase) &gt;5*ULN&#xD;
&#xD;
          2. Any secondary IgA nephropathy caused by Henoch-Schönlein purpura, ankylosing&#xD;
             spondylitis, systemic lupus erythematosus, sjogren syndrome, viral hepatitis, liver&#xD;
             cirrhosis, rheumatoid arthritis, mixed connective tissue disease, polyarteritis&#xD;
             nodosa, erythema nodosum, psoriasis, ulcerative colitis, crohn's disease, tumor, AIDS&#xD;
             ,etc.;&#xD;
&#xD;
          3. Any nephropathy with special pathologic or clinical types, such as nephrotic syndrome,&#xD;
             crescentic glomerulonephritis(with &gt;50% of biopsied glomeruli), IgA nephropathy with&#xD;
             minimal change disease (MCD-IgAN); and IgA nephropathy requiring corticosteroids&#xD;
             treatment.&#xD;
&#xD;
          4. Suffering from cardiovascular and cerebrovascular events (myocardial infarction,&#xD;
             unstable angina, ventricular arrhythmia, New York heart association grade III-IV heart&#xD;
             failure, stroke, etc.) within the last 12 weeks;&#xD;
&#xD;
          5. Treating with systemic corticosteroids drug(excluding topical or nasal steroids)&#xD;
             within 6 months prior to randomizing;&#xD;
&#xD;
          6. Treating with systemic immunosuppressor within 6 months prior to randomizing:&#xD;
             cyclophosphamide, azathioprine, mycophenolate mofetil, leflunomide, tacrolimus,&#xD;
             cyclosporine, rituximab, tripterygium wilfordii, etc.;&#xD;
&#xD;
          7. Requiring hospitalization or intravenous antibiotics treatment due to active infection&#xD;
             within 6 months prior to randomizing;&#xD;
&#xD;
          8. Active tuberculosis or latent carrier;&#xD;
&#xD;
          9. Positive in herpes zoster, HIV antibody or HCV antibody;&#xD;
&#xD;
         10. Active hepatitis or severe liver disease, and HBV infection (According to the HBV&#xD;
             screening test, ①excluded the HBsAg-positive; ②HBsAg-negative and HBcAb-positive, the&#xD;
             HBV-DNA should be tested to determine the situation: the HBV-DNA positive subjects&#xD;
             should be excluded, while the HBV-DNA negative subjects can participated in.)&#xD;
&#xD;
         11. With malignant tumors;&#xD;
&#xD;
         12. Pregnancy or lactation, or patients with family planning during the experiment;&#xD;
&#xD;
         13. Inevitably administrate nephrotoxic drugs during the study period;&#xD;
&#xD;
         14. Allergy to human biological products;&#xD;
&#xD;
         15. Receiving any other experimental drug 4 weeks or 5 times half-life of the experimental&#xD;
             drug (up to the longer time) prior to randomizing;&#xD;
&#xD;
         16. Not suitable for the study judged by investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University people's hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

